The Compounding Price Era Is Ending. Here Is the New Floor.
The $150–$300 compounded market existed because branded pricing was above $1,000. That gap has closed from both directions, and the arithmetic that built this market no longer holds.
Bottom line
- Compounded GLP-1s were generally priced around $150–$300/month against branded pricing above $1,000.
- Foundayo self-pay now starts at $149/month for the lowest dose.
- The FDA proposed on April 30, 2026 to remove semaglutide, tirzepatide, and liraglutide from the 503B Bulks List.
- Expect compounded pricing to stop being the deciding factor for most patients.
Every market has an origin story in arithmetic. The compounded GLP-1 market's story was a spread: roughly $150 to $300 per month for compounded product against branded pricing above $1,000. A difference of that size justifies a great deal of inconvenience and a meaningful amount of risk.
Both ends of that spread have moved.
How the spread closed
| Period | Compounded | Approved brand | Spread |
|---|---|---|---|
| 2022–2024 | ~$150–$300/mo | Above $1,000/mo | Roughly $700–$850/mo |
| September 2026 | ~$99–$299/mo oral | From $149/mo self-pay (Foundayo) | Overlapping ranges |
Approved-product pricing reflects Foundayo self-pay at the lowest dose. Compounded figures reflect providers listed on this site, September 2026.
What moved the top of the range
Two approvals. Oral semaglutide — the Wegovy pill — was approved in December 2025 and launched in January 2026. Foundayo was approved April 1, 2026, priced from $149 per month self-pay at the lowest dose, as little as $25 per month for eligible commercially insured patients with a savings card, and $50 per month for eligible Medicare Part D patients from July 1, 2026.
Manufacturers did not do this out of generosity. They did it because a large compounded market had demonstrated that substantial demand existed below $300 per month, and because capturing that demand directly is better than litigating against it indefinitely.
The compounded market's most durable achievement may be that it forced manufacturer pricing down. Whatever you think of how it operated, the demand it revealed at sub-$300 price points is visible in what the approved oral products launched at.
What is moving the bottom of the range
Regulatory and legal pressure, not competition. On April 30, 2026 the FDA said it wants to end most compounding of semaglutide, tirzepatide, and liraglutide, finding there is no longer a clinical need for certain compounded versions, and proposing to bar 503B outsourcing facilities from bulk compounding them.
In parallel, Novo Nordisk sued Hims & Hers in February 2026 and has said it has filed 132 suits across 40 states, winning 44 permanent injunctions. Eli Lilly sued compounders Strive Pharmacy and Empower in April 2025 and four telehealth companies weeks later.
Supply-side contraction does not usually produce lower prices.
Current pricing across both sides of the market
All providers below are paid partners. Prices shown were recorded at publication and change without notice — always confirm on the provider's own page before you enrol.
Cash-pay marketplace for appointments with clinicians who prescribe FDA-approved brand-name medication only. No compounded product.
Check current pricing Paid partner linkCompounded oral tablets. Lowest verified oral semaglutide price among providers we list without a regulatory flag.
Check current pricing Paid partner linkInjectable semaglutide only. No oral formulation.
Check current pricing Paid partner linkSublingual semaglutide and oral tirzepatide, compounded.
Check current pricing Paid partner linkWhat a rational buyer does now
If the difference is under about $50/month
Take the FDA-approved product. At that spread you are paying a small premium for product review, supply certainty, defined dose tiers, and no exposure to the wind-down. That is a good trade.
If the difference is $100/month or more
The compounded option is defensible if the provider is verifiable and the formulation is disclosed. Budget for a transition anyway, because supply durability is the risk you are accepting.
If the compounded price seems unusually low
Check why. The two lowest oral prices among providers we list come from companies carrying FDA warning letters — Strut Health, letter #721448, and Sprout Health, letter #715879. That is not a reason to assume harm, but it is a reason to know what you are buying and from whom.
If your compounded supplier stops filling, you need an appointment, a new prescription, and product in hand before your last dose. An unplanned gap in GLP-1 therapy means re-titrating, which means weeks of side effects you have already been through once. That is a real cost, and it belongs in the comparison.
Where the floor settles
The honest forecast is that compounded pricing stops being the deciding factor for most patients within the next year, and that what survives is patient-specific compounding for people with a documented clinical reason the approved product does not work — priced as a specialty service rather than as a discount alternative.
Sources & price verification
- Pharmacy Times, reporting on historic compounded pricing of roughly $150 to $300 per month against branded pricing above $1,000.
- AJMC, reporting on Foundayo pricing tiers and Medicare Part D access from July 1, 2026.
- FDA proposed action on 503B Bulks List status, April 30, 2026.
- Medscape, “FDA Proposes End to Mass GLP-1 Compounding,” May 1, 2026.
- Drug Discovery Trends, reporting on Novo Nordisk and Eli Lilly litigation totals.
- FDA warning letters #715879 and #721448.